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Abstract: Background: Clozapine is of high clinical relevance for the management of both treatment-
resistant schizophrenia and psychotic disturbances with concurrent drug misuse. Although the 
molecule presents with a range of well-known side-effects, its discontinuation/withdrawal 
syndrome has been only anecdotally described. Aims: the 2005–2018 European Medicines Agency 
(EMA) dataset of Adverse Drug Reactions (ADRs) was analyzed to identify and describe possible 
clozapine withdrawal- and misuse-/abuse-/dependence-related issues. Method: A descriptive 
analysis of clozapine-related ADRs was performed when available, data on ADRs’ outcome, dosage, 
and possible concomitant drug(s) were considered. Results: Out of 11,847 clozapine-related ADRs, 
some 599 (5.05%) were related to misuse/abuse/dependence/withdrawal issues, including 258 
withdrawal-related (43.1%); 241 abuse-related (40.2%); and 80 intentional product misuse-related 
(13.3%) ADRs. A small number of overdose- and suicide-related ADRs were reported as well. 
Clozapine was typically (69.2%) identified alone, and most (84.7%) fatalities/high-dosage intake 
instances were reported in association with a history of substance abuse. Conclusions: Previous 
suggestions about the possibility of a clozapine discontinuation/withdrawal occurrence are here 
supported, but further studies are needed. However, the misuse/abuse cases here identified might 
be difficult to interpret, given the lack of studies highlighting the possible recreational use of 
clozapine. The high-dosage intake, fatal outcomes and clozapine/polydrug abuse issues reported 
here may, however, be a reason for concern. 
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1. Introduction 
Clozapine was first synthesized in 1959 [1] and made available on the European market in 1971 
for the treatment of schizophrenia [2]. If compared with remaining first-generation antipsychotic 
agents, clozapine is characterized by a lack of extrapyramidal side-effects [2]. After having been 
withdrawn from the European market in 1976 due to fatal cases of agranulocytosis, clozapine was 
approved by the Food and Drug Administration (FDA) in 1989 for treatment-resistant schizophrenia 
[2,3]. It was then approved in the USA in 2002 for reducing recurrent suicidal behavior in patients 
with schizophrenia or schizoaffective disorder. Other unlicensed uses include treatment-resistant 
bipolar disorder, aggression in patients with psychosis, and other brain disorders unresponsive to 
remaining treatments [4]. 
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1.1. Pharmacodynamic Considerations 
Clozapine is a dibenzodiazepine designated as a Multi-Acting Receptor-Targeted Antipsychotic 
(MARTA), deriving its therapeutic effects from its action across various neurotransmitter systems 
[4,5]. In fact, a combination of pharmacological effects is unique to clozapine: (1) although the 
molecule presents with affinity levels for a range of dopamine/DA receptors (e.g., D1, D2, D3, D4, 
and D5; [6]), the blockade of dopamine 2 and 4 receptors is particularly relevant, with a preferential 
affinity for D4 over D2 receptors; this blockade seems to be effective in reducing positive symptoms 
of psychosis and stabilizing affective symptoms [4]; (2) 5-hydroxytryptamine/5-HT 2A receptor 
antagonism, causing enhancement of DA release in certain brain regions, and thus reducing motor 
side-effects and possibly improving cognitive and affective symptoms associated with schizophrenia 
[4]. Conversely, the clinical effects of the reported interactions at 5HT2C; 5HT1A; 5-HT6; and 5-HT7 
receptors [6] might be less clear; (3) α2C-adrenergic receptor blockade; this may contribute to the 
clozapine-related improvement of cognitive function [7]; (4) significant antimuscarinic and 
antihistaminergic H1 effects, which may well contribute to the central effect [8]; and (5) possible 
modulatory actions on a dysfunctional glutamatergic system, improving schizophrenia symptoms 
and contrasting illness progression [1,4,9–11]. More precisely, clozapine interacts with the N-methyl-
D-aspartate (NMDA) receptor complex, affecting either the glycine site of the NMDA receptor or 
tentatively inhibiting the glycine transporter [12]. Moreover, both clozapine and its major metabolite 
N-desmethylclozapine behave as: (i) delta-opioid receptor agonists [13–17]; (ii) cannabinoid CB1 
receptor agonists [18]; and (iii) antagonists at muscarinic receptors [8]. Indeed, these i-iii 
pharmacological activities are, per se, typically associated with the occurrence of pleasurable effects 
[19–22], which could suggest a theoretical potential for clozapine to be misused by vulnerable 
individuals. Finally, further pharmacological clozapine activities which should be better understood 
in terms of their clinical effects may include both interaction with GABA-B receptors [22]; and 
antagonistic actions at D (2)/D (3)/D (4) receptors [23]. 
The therapeutic response depends on plasma clozapine concentrations, which may be 
influenced by many factors such as age, gender, and smoking [5], and should normally reach 350 
ng/mL [4,5]; levels greater than 700 ng/mL are often not well tolerated [4]. Clozapine is metabolized 
by CYP450 enzymes, specifically by CYP450 1A2, 2D6 and 3A4 enzymes [5], and its metabolism may 
be influenced by CYP450 1A2 inhibitors, such as fluvoxamine and ciprofloxacin [14]. Remaining 
interactions may occur with both strong CYP450 2D6 inhibitors (e.g., bupropion, duloxetine, 
paroxetine, fluoxetine) and strong CYP450 3A4 (e.g., ketoconazole) inhibitors [4,15]. 
1.2. Clozapine abuse issues and Substance Use Disorders 
Substance use disorders (SUDs), typically involving alcohol, cannabis, and cocaine, commonly 
occur in patients with schizophrenia, supposedly due to epidemiological and genetic determinants 
of risk for both psychosis and addiction [1,16]. This co-occurrence (‘dual diagnosis’) has a negative 
effect on the course of schizophrenia, due to increased rates of hospitalization, decreased compliance 
with medication, increased violence and suicide, general deterioration of the patients’ condition, and 
overall increased societal costs [1,17]. In particular, the positive symptoms of schizophrenia are 
generally exacerbated by the intake of stimulant drugs, such as cocaine, amphetamine derivatives 
[24], and synthetic cathinones [25]. Due to clozapine’s effectiveness, there has been support for 
considering the molecule in limiting substance use in patients with schizophrenia [26], to achieve 
both a reduction in substance use [27,28] and an improvement in positive/negative schizophrenia 
symptoms [29]. Additionally, differently from other antipsychotics, such as quetiapine, which has 
showed in recent years to be a strong potential for misuse and abuse [30–33], the recreational use of 
clozapine has not been noted in the literature. Conversely, clozapine withdrawal is a phenomenon 
which has already been described, even at therapeutic dosages [9]. However, the risk of withdrawal 
may arguably be significant only when a psychoactive molecule is being misused/ingested at higher 
dosages. Since SUD patients may be vulnerable to misuse prescribed medications, one could argue 
that it is relevant to identify and assess any possible clozapine misuse/abuse/withdrawal and 
dependence issues. 
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1.3. Aims 
We aimed here at identifying and describing the number of European Medicines Agency (EMA) 
database cases of misuse, abuse, dependence, and withdrawal specifically relating to clozapine; 
suicide-related cases and fatalities were also considered. 
2. Methods 
2.1. Data source and acquisition 
EudraVigilance (EV) manages and analyzes information on suspected Adverse Drug Reactions 
(ADRs) to medicines that have been authorized in the European Economic Area (EEA), according to 
Directive 2001/83/EC and Regulation (EC) No 726/2004 [34]. In order to investigate the aspects above, 
EV was specifically requested to provide all Level 2A data [34] comprising case reports of clozapine-
related misuse, abuse, dependence, and withdrawal ADRs, which were obtained in the form of line 
listings, relating to the 2005–June 2018 time-frame. Differently from the publicly available data from 
the EV website, Level 2A data were presented as Excel sheets divided into information sections 
reporting in a standardized format according to the Medical Dictionary for Regulatory Activities 
(MedDRA), which is the internationally agreed list of terms that supports the coding of ADRs [35], 
which are identified through Preferred Terms (PT). Indeed, MedDRA is a comprehensive and highly 
standardized medical terminology developed by the International Council for Harmonization of 
Technical Requirements for Pharmaceuticals for Human Use (ICH) (https://www.meddra.org/) in the 
late 1990s to facilitate the international sharing of regulatory information for medical products. Such 
listings showed all information related to the ADR, the patient, the drug, the reporter, and the 
diagnosis. In line with previous studies from our group [36–39], the ADRs considered here were, per 
se, voluntary and unsolicited communications [34] reported by both Regulatory Authorities of the 
EU Member States where the reaction occurred and/or by the Marketing Authorization Holders for 
those ADRs occurring outside the EEA. Individual Case Safety Reports, such as voluntary reports, 
refer to the format and content for the reporting of one or several suspected ADRs in relation to a 
medicinal product that occur in a single patient at a specific point of time [40]. ‘Suspect’ ADRs were 
selected, meaning clozapine was considered as ‘suspected’ for the reaction reported [34]. Within the 
standardized MedDRA Query (SMQ) ‘drug abuse, dependence and withdrawal’ section, we 
identified the following ADRs: dependence, drug abuse, drug abuser, drug dependence, drug 
diversion, drug withdrawal convulsions, drug withdrawal syndrome, drug withdrawal neonatal 
syndrome, intentional product misuse, product use issue, substance abuse, and withdrawal 
syndrome. For the definition of ‘abuse’; ‘addiction’; ‘dependence’; and ‘misuse’ please refer to 
references [35–40]. Moreover, in accordance with MedDRA, ‘withdrawal’ is identified in association 
with the abrupt cessation or reduction in intake of a drug in a habituated person. A substance-specific 
syndrome may follow, with withdrawal symptoms varying according to the psychoactive substance 
used and generally opposite the acute effects of drug. These include nonspecific symptoms e.g., 
nausea, diarrhea or constipation, profuse sweating, increase in respiratory rate, and tachycardia; 
remaining common symptoms include anxiety, restlessness, irritability, insomnia, and impaired 
attention [35]. 
2.2. Data analysis 
Each case report may refer to one or more reporter; one or more ADR(s); as well as to one or 
more medicinal product(s). Therefore, a case may be represented by more than one row in the other 
line listings. All rows of the case have the same ‘EV Local Report Number’, unequivocally identifying 
an individual case. Thus, the number of suspected ADRs can be different from the number of case 
reports as one case report may refer to several suspected ADRs. Moreover, the number of patients 
can be different from the number of case reports as a patient may have been described in more than 
one case. Finally, ADRs’ numbers differed from those referring to case reports/single patients since 
different reporters/senders could have independently flagged the same ADR to the EMA. 
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Patients’ data were analyzed using a range of parameters, including: socio-demographic 
characteristics (age and gender); source/reporter country (EEA or non-EEA) and reporter 
qualification (i.e., pharmacist, physician); outcomes (fatal, recovered, resolved); clozapine dosage; 
possible concomitant drug(s); and diagnosis/reporter’s comments, if recorded [37]. The analysis 
included cases of overdoses, suicides, and fatalities. 
Suicidal behavior was here defined as ‘completed suicide’, ‘intentional self-injury’, ‘suicidal 
behavior’, ‘suicidal ideation’, ‘suicide attempt’, ‘self-injurious ideation’, and ‘intentional self-injury.’ 
‘Overdose’, including ‘intentional overdose’, was not necessarily interpreted as being a suicidal 
attempt [35]. The analysis included here both a descriptive study of the dataset and the Confidence 
Interval (CI) values [41]. 
2.3. Ethics’ issues 
Complying with applicable Personal Data Protection legislation (Regulation (EC) No 45/2001 
and Regulation (EC) No 1049/2001 on the protection of privacy and integrity of individuals, certain 
data elements, including names/identifiers of individuals involved or country-specific information 
were not disclosed by the EMA to safeguard the identity of individuals [42]. The study was ethically 
approved in March 2018 by the University of Hertfordshire Ethics’ Committee, with reference 
number LMS/PGR/UH/03234. 
3. Results 
The EMA dataset included a total of 13,596 clozapine-related ADRs. A total of 11,847 ADRs were 
considered as ‘suspect’, i.e., as suspected to be related with clozapine. Of those, 599/11,847 (5.05% CI 
95% 597–601) related to misuse/abuse/dependence/withdrawal ADRs and were associated with 559 
unique subjects. These included: 258 ADRs (258/599 = 43.1% CI 95% 256–260) relating to ‘withdrawal 
syndrome’ issues; 241 abuse-related ADRs (241/599 = 40.2% CI 95% 239–242); and 80 ADRs (80/599 = 
13.3% CI 95% 76–84) relating to ‘intentional product misuse.’ A small number of overdose- (n = 29) 
and suicidal behavior-related ADRs (n = 29) were reported here, resulting in death, respectively, in 
two and 11 cases (Table 1). 
Table 1. Analysis of the EudraVigilance (EV) clozapine-related misuse/abuse/dependence and 
withdrawal ADRs (2005–June 2018). 
EudraVigilance (EV) Clozapine-Related 
Misuse/Abuse/Dependence and Withdrawal ADRs (2005–June 
2018) 
n 
Total “suspect” clozapine-related ADRs 11,847 
Clozapine-related ‘abuse, dependence and withdrawal’ ADRs 599 (CI 95% 595–603) 
(n individual cases = 559)  
Drug abuse 198 
Drug abuser 1 
Substance abuse 42 
Dependence 7 
Drug dependence 6 
Drug diversion 1 
Intentional product misuse 80 
Product use issue 4 
Drug withdrawal convulsions 1 
Drug withdrawal neonatal syndrome 1 
Drug withdrawal syndrome 91 
Withdrawal syndrome 165 
  
Further issues emerging from the analysis of clozapine ADRs’ dataset  
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Intentional overdose 12 
Overdose 17 
Completed suicide 9 
Intentional self-injury 4 
Suicidal behavior 1 
Suicidal ideation 4 
Suicide attempt 7 
Self-injurious ideation 4 
Patients were typically males (379/559 = 67.8% CI 95% 378–380), in the 18–65 years age range. 
Most typical senders were pharmaceutical companies (303/559 = 54.2% CI 95% 301.5–304.5) and 
regulatory authorities (241/559 = 43.11% CI 95% 239–243) (Table 2). 
Table 2. Description of clozapine-related misuse, abuse, dependence and withdrawal cases. F: 
female; M: male; N: no; Y: yes. 
Clozapine-Related Misuse, Abuse, 
Dependence and Withdrawal Cases n of Unique Patients 
 559 
Age range (years) 
3 neonates, 
1 child (5 years), 
2 adolescents (15–16 years), 
78 adults (18–65 years), 
1 elderly (67 years), 
474 Not specified  
Gender 
171 F, 
379 M, 
9 Not Specified 
Sender 
241 Regulatory authority, 
303 Pharmaceutical company, 
9 Other (distributor, study sponsor, contract 
research organization), 
6 Not Specified 
Outcome  
Resulted in death 46 Y, 448 N, 65 Not Specified 
Life threatening 35 Y, 447 N, 77 Not Specified 
Required a prolonged hospitalization 298 Y, 219 N, 42 Not Specified 
Disabling 8 Y, 467 N, 84 Not Specified 
The number of cases increased year by year, with a peak in 2008 (120/559 cases) (Figure 1). 
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made available, these cases were typically described as ‘intentional self-injury’, ‘completed suicide’, 
and ‘drug abuse’). 
 
Figure 2. Dosages of clozapine reported to the EudraVigilance (EV) dataset of clozapine-related 
misuse, abuse, dependence, withdrawal ADRs. 
Clozapine was the sole molecule reported in 387/559 (69.2% of cases; CI 95% 386–388); remaining 
drugs included: first/second generation antipsychotics (55/559 cases; 9.8%); benzodiazepines 
(clonazepam, diazepam, and lorazepam; 54/559 cases; 9.7%); antidepressants (citalopram, 
escitalopram, sertraline, and venlafaxine; 33/559 cases; 5.9%); and mood stabilizers (valproic acid, 
carbamazepine, lamotrigine, lithium, and gabapentin; 20/559 cases; 3.6%). Illicit drugs most typically 
reported here were opioids (15/559 cases), amphetamines (10/559), cannabis, and alcohol (each in 
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seven cases). In 30 cases, two or more prescribed/recreational drugs were recorded in association with 
clozapine (Table 3). 
Table 3. Clozapine alone or in combination rates of identification, as recorded by the EudraVigilance 
(EV) dataset of misuse, abuse, dependence, and withdrawal cases. 
Clozapine-Related Misuse, Abuse, Dependence and Withdrawal Cases 
Recorded by the EudraVigilance (EV) Dataset Tot (n = 559) 
Clozapine ingested as a lone drug 387 (69.2%) 
Clozapine identified in combination with remaining drugs 172 (30.7%) 
Prescribing drugs  
Other antipsychotics 55 
Benzodiazepines 54 
Antidepressants 33 
Mood stabilizers 20 
Z-drugs 4 
Recreational drugs  
Opioids 15 
Amphetamine derivatives 10 
Cannabis 7 
Alcohol 7 
Cocaine 4 
Ketamine 1 
The ADRs required in most cases a prolonged hospitalization (298/559 = 53.3% CI 95% 296.5–
299.5), while some 46 cases (46/559 = 8.2%) resulted in death (Tables 2 and 4). Of these 46 clozapine-
related fatalities, 39 (84.7%) were associated with a previous history of substance abuse (Table 4). 
Table 4. Description of the clozapine-related fatalities’ cases reported to the EudraVigilance (EV) 
dataset (2005–June 2018). F: female; M: male. 
  
Clozapine 
Dosage 
(mg) 
Concomitant 
Drugs 
Medical History 
Reactions according to the 
MedDRA Dictionary 
(Preferred Terms-PT) 
1 
M, 
Adult 
(30 
yy) 
200 mg 
Benzodiazepines 
Alcohol 
 
Intentional product misuse; 
Antipsychotic drug level 
increased (clozapine 
plasmatic 1.1 mg/mL); Blood 
pressure decreased; Loss of 
consciousness; Poisoning; 
Dysarthria; Loss of 
consciousness; Blood alcohol 
increased 
2 
M, 
Adult 
(48 
yy) 
N/A 
Cocaine 
Opioids 
Z-drugs 
Hypertension; 
Schizophrenia; Chronic 
obstructive pulmonary 
disease; 
Arteriosclerosis 
Substance abuse; Toxicity to 
various agents 
3 
M, 
Adult 
(25 
yy) 
300 mg 
Benzodiazepines 
Opioids 
 
Cardiac arrest; Arrhythmia 
Toxicity to various agents 
(methadone and clozapine); 
Drug abuse; Drug level 
increased (methadone and 
clozapine) 
4 
M, 
Adult 
N/A Opioids 
Hypertension; 
Alcoholism; 
Pulmonary embolism; 
Drug abuse 
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(44 
yy) 
Depression; Epigastric 
discomfort; Anxiety 
5 
M, 
Adult 
400 mg Alcohol  
Liver function test abnormal; 
Blood alkaline phosphatase 
increased; Gamma-glutamyl 
transferase increased; 
Asphyxia; Alcohol abuse; 
Drug abuse (heroin) 
6 
M, 
Adult 
(24yy) 
N/A Alcohol Anemia Drug abuse (Clozaril abuse) 
7 F 300 mg  
Alcoholism; Mental 
impairment; Depression; 
Treatment 
noncompliance; 
Deep vein thrombosis 
Death; Withdrawal 
syndrome; 
Acute psychosis; Cognitive 
disorder; Amnesia; Speech 
disorder; Gait disturbance; 
Chills 
8 
F, 
Adult 
(54yy) 
350 mg Benzodiazepines  
Withdrawal syndrome; 
Insomnia; Completed suicide 
9 
M, 
Adult 
(66 
yy) 
N/A   
Completed suicide; Drug 
abuse 
10 
F, 
Adult 
(25yy) 
N/A Antidepressants  
Completed suicide; Drug 
abuse 
11. 
M, 
Adult 
(31yy) 
N/A   
Completed suicide; Drug 
abuse 
12 M N/A  
Obesity; 
Gastroesophageal reflux; 
Drug abuse 
Drug abuse; Death 
13 F N/A 
Cocaine 
Benzodiazepines 
Opioids 
Drug dependence 
Drug abuse (cocaine, leponex 
and probably 
benzodiazepines); Death; 
Hyperthermia malignant; 
Cardiac arrest; Circulatory 
collapse; Delirium 
14 M N/A  Hepatitis 
Drug abuse (possible use of 
non-prescribed drugs); Death 
15 M N/A  
Salivary hypersecretion; 
Drug abuse (crack 
cocaine, marijuana, 
alcohol); Extrapyramidal 
disorder 
Nonspecific reaction; 
Treatment noncompliance; 
Drug abuse (mixed 
polysubstance abuse); Death 
16 F N/A 
Mood stabilizers 
Antipsychotics 
 Drug abuse 
17 M 1000 mg  
Hypercholesterolemia; 
Substance abuse; 
Hypertension; 
Schizophrenia; 
Gastro-esophageal reflux 
disease 
Hematemesis; Drug abuse; 
Cardiac arrest; Completed 
suicide; Toxicity to various 
agents; Intentional overdose; 
Resuscitation; Seizure; 
Tachycardia 
18 
F, 
Adult 
(27yy) 
N/A   Drug abuse 
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19 
M, 
Adult 
(30yy) 
N/A   
Myocardial infarction; Drug 
abuse; Eye swelling; 
Glossodynia; Tongue coated; 
Swollen tongue 
20 F N/A   
Intentional self-injury; 
Meningioma; Drug abuse; 
Hypoglycemia; Peripheral 
venous disease; Hepatic 
steatosis; Scar; Pneumonia; 
Bronchitis; Arteriosclerosis 
coronary artery; Purulent 
discharge; Pulmonary 
congestion; Death 
21 
M, 
Adult 
(26yy) 
800 mg   
Coronary artery disease; 
Drug abuse; Hallucination, 
auditory; Epilepsy; Depressed 
mood 
22 
M, 
Adult 
(31yy) 
N/A   Death; Substance abuse 
23 M N/A  
Surgery; Intentional self-
injury; Bipolar disorder 
Agitation; Death; Drug abuse; 
Suicidal ideation; Nasal 
septum deviation  
24 
M, 
Adult 
(30yy) 
N/A   
Autonomic nervous system 
imbalance; Catatonia; Drug 
withdrawal syndrome; 
Dyskinesia; Neuroleptic 
malignant syndrome; 
Psychotic disorder 
25 
M, 
Adult 
(36yy) 
N/A   
Alcohol abuse; Drug abuse; 
Myocardial infarction; 
Coronary artery disease 
26 M 200 mg   Drug abuse; Obesity 
27 
M, 
Adult 
(34yy) 
350 mg   
Circulatory collapse; 
Intentional product misuse; 
Cardiopulmonary failure 
28 
M, 
Adult 
(33yy) 
N/A 
Benzodiazepines 
Opioids 
 
Death; Drug abuse (heroin, 
temazepam) 
29  N/A  
Arm amputation; Drug 
dependence (including 
cannabis, benzodiazepines 
and heroin); Limb 
reduction defect; Alcohol 
use 
Drug abuse; Loss of 
consciousness; Hypothermia 
30 
M, 
Adult 
(31yy) 
N/A   
Abnormal behavior; 
Myocardial infarction; 
Drug abuse (heroin, cocaine); 
Psychomotor hyperactivity; 
Peripheral coldness; 
Unresponsive to stimuli; 
Arteriosclerosis coronary 
artery; Blood glucose 
decreased 
31. 
F, 
Adult 
(72yy) 
200 mg Opioids 
Schizophrenia; 
Depression; Somnolence; 
Anxiety 
Movement disorder; Sudden 
death; Drug abuse 
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32. 
M, 
Adult 
(27yy) 
400 mg Antipsychotics 
Asthma; Nicotine 
dependence; Drug abuse; 
Obesity; Substance use; 
Diabetes mellitus; Mental 
disorder; Alcohol use 
Asphyxia; Substance abuse 
33. 
M, 
Adult 
(50 
yy) 
550 mg   
Hypoxic-ischemic 
encephalopathy; Drug abuse 
(cocaine); Pulmonary 
hemosiderosis; Pulmonary 
edema; Cardiac arrest; 
Left ventricular hypertrophy; 
Arteriosclerosis coronary 
artery; Aortic arteriosclerosis; 
Myocardial fibrosis; Hepatic 
steatosis; Spleen congestion 
34. 
M, 
Adult 
(29yy) 
1000 mg Opioids Schizophrenia Substance abuse (heroin) 
35. 
F, 
Adult 
N/A Antidepressants  Drug abuse 
36. 
M, 
Adult 
(34yy) 
700 mg  
Schizophrenia; Nicotine 
dependence; 
Drug abuse 
Cardiac arrest; Substance 
abuse 
37. 
F, 
Adult 
(28yy) 
N/A Antidepressants  Drug abuse 
38. M 100 mg  
Blood cholesterol 
increased; Bipolar 
disorder; 
Gastroesophageal reflux; 
Schizoaffective disorder; 
Diabetes mellitus 
Sudden death; Drug abuse 
(cocaine and another illicit 
drug) 
39. 
F, 
Adult 
(50yy) 
N/A Alcohol 
Drug abuse; Drug 
dependence 
Completed suicide; Toxicity 
to various agents; Drug abuse 
(propofol) 
40. M N/A  
Product use issue; 
Psychotic disorder 
Product use issue; Drug level 
increased (clozapine levels in 
the 600,000 s); Death; Adverse 
event; Psychotic disorder; 
Intentional product misuse 
41. M N/A   
Drug withdrawal syndrome; 
Memory impairment; 
Disorientation; 
Completed suicide 
42. 
F, 
Adult 
(28yy) 
N/A Antidepressants  
Toxicity to various agents; 
Drug abuse 
43. 
M, 
Adult 
(31yy) 
700 mg  
Anxiety; Psychotic 
disorder; Depression 
Completed suicide (suicide 
due to overdose on 
clozapine); 
Intentional product misuse; 
Overdose; Adverse event 
44. M N/A   
Completed suicide (patient 
jumped to his death); 
Withdrawal syndrome 
(periodically he would refrain 
from taking the medication, 
thus suffering 
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withdrawal/Initially 
withdrawal symptoms would 
consist of disorientation after 
2–3 days and memory 
impairment after 4–7 days) 
45. M N/A   
Death; Withdrawal syndrome 
(withdrawal symptoms from 
the capsule form of Clozaril 
antipsychotic medication) 
46. 
M, 
Adult 
(58yy) 
100 mg  
Alcohol use; 
Hypertension 
Drug abuse; Vomiting; 
Asphyxia; Prescription drug 
used without a prescription 
(abuse of clozapine 100 mg 
tablets) 
In a number of cases, reporters had omitted some relevant details, including diagnosis, drugs 
involved, and, more importantly, both the white blood cell (WBC) and the absolute neutrophil count 
(ANC) results. Out of a total of 599 ADRs, referring to 559 individual cases, some 149 ADRs (42 
individual cases) mentioned that the WBC count had been carried out. However, the results were 
reported in only 123 ADRs (32 individual cases). For 68 of these ADRs, the WBC/ANC count was 
within the normal range; while 42 and 13 ADRs were, respectively, associated with either leukopenia 
or increased WBC count levels. However, since modifications overtime of WBC count levels were not 
reported, it would be problematic to unequivocally conclude from here if clozapine had been stopped 
in association with the occurrence of WBC count abnormalities. 
A total of 28 cases reported here catatonia, six of which were specifically described as being 
associated with clozapine withdrawal issues; further reporters’ comments relating to overdose, 
suicidal behavior, withdrawal, and abuse issues are listed in Table 5. 
Table 5. Reporter’ comments recorded in the line listing; EudraVigilance (EV) clozapine-related 
misuse/abuse/dependence and withdrawal ADRs (2005-June 2018). 
 Comments in the ADRs Reported in the Dataset 
Overdose and suicidal 
behaviour ADRs 
1. “Clozapine overdose in suicidal attempt” 
2. “Patient stopped treatment and then took an overdose of  
about 2800 mg” 
3. “Clozapine levels in the 600,000’s possible overdose” 
4. “Clozapine overdose of 3000 mg/took two weeks supply 
of Clozaril as 4200 mg (300 mg × 14 dd)” 
5. “Clozapine overdose” 
6. “Took an overdose of 5600 mg” 
7. “The patient took 1300 mg for intentional self-injury” 
8. “Suicide due to overdose on clozapine”  
Withdrawal and clozapine 
discontinuation ADRs 
1. “Clozaril withdrawal due to non-compliance” 
2. “Withdrawal reaction cholinergic rebound” 
3. “Anticholinergic withdrawal syndrome” 
4. “Withdrawal psychotic episode” 
5. “Sudden withdrawal with Clozaril” 
6. “Clozaril withdrawal psychosis” 
7. “Psychotic decompensation after clozapine 
discontinuation” 
8. “Relapse psychosis” 
9. “Experiencing extremely negative reactions due to going 
off this medication” 
10. “Serotonin syndrome associated with clozapine 
withdrawal” 
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11. “Withdrawal agitation” 
12. “Tachycardia and high BP possibly due to Clozaril 
withdrawal” 
13. “Acute clozapine withdrawal” 
14. “Withdrawal symptoms from Clozaril” 
15. “Compatible with withdrawal effects arising from the 
abrupt discontinuation of clozapine” 
Abuse of clozapine  
1. “Abusing Clozaril taking more than he needs” 
2. “Clozaril was prescribed for family members” 
3. “Took his wife’s Clozaril to help him sleep” 
4. “He depended on clozapine” 
5. “Died because of clozapine and alcohol” 
6. “Clozapine as a drug of abuse” 
7. “Clozaril misuse” 
8. “Abuse of Leponex” 
9. “Patient possibly has used Leponex as drug of abuse or 
he bought Leponex for drug abuse by others” 
4. Discussion 
To the best of our knowledge, this is the largest collection of literature data relating to clozapine 
withdrawal and misuse/abuse/dependence cases. Our analysis found 599 ADRs of interest (relating 
to 559 individuals), representing 5.05% of all 11,847 reports submitted to the EMA EV between 2005 
and 2018 and judged as ‘suspect.’ In contrast with the related knowledge on this topic, mostly focused 
on small case reports/series [10,43–48], current findings referred to high numbers of patients 
presenting with clozapine withdrawal and misusing issues. 
Clozapine ADRs of interest showed a peak in 2008, but an overall increase was observed 
between 2010 and 2018. One could argue that this upward trend may have been associated with a 
range of factors, including the increasing rates of worldwide availability of clozapine due to an 
overwhelming evidence of its effectiveness [2,49–51] and/or a major awareness of the relevant and 
significant impact of pharmacovigilance processes and issues, resulting in a rise of spontaneous 
reporting practices related to safety monitoring of medicinal products in general [52]. 
Withdrawal cases collected here were recorded according to the related PTs defined in the 
MedDRA dictionary [35], where withdrawal is described as “the abrupt cessation of a drug use in a 
habituated person; and a substance specific syndrome following cessation or reduction in intake of a 
psychoactive substance previously used regularly”. Clozapine withdrawal/discontinuation ADRs 
were the most frequently reported and, as such, current findings confirmed and expanded on 
previous anecdotal data [6,53,54]. In association with a sudden discontinuation of clozapine, which 
may be required in cases of blood dyscrasia or suspected myocarditis, instances of withdrawal have 
already been reported [6,44,54,55]. It is of clear interest that a case of clozapine withdrawal neonatal 
syndrome was specifically mentioned here as well. The clozapine multi-receptor 
agonism/antagonism is likely responsible for the occurrence of discontinuation/withdrawal 
symptoms. Indeed, the clozapine pharmacodynamic profile may well include: a) a dopaminergic 
super-sensitivity, with the risk of a dopaminergic psychosis and symptoms such as dystonias, 
dyskinesias, and catatonia [38,56–59]; b) a cholinergic rebound, inducing in vulnerable patients a 
rapid worsening of psychosis, agitation, confusion, insomnia, and symptoms including nausea, 
vomiting, diarrhea, headache, diaphoresis, and abnormal movements, such as dystonias and 
dyskinesias [6,54,56,57,60–64]. Consistent with this, symptoms appear to regress rapidly with the 
help of anti-cholinergic drugs; c) a serotonergic syndrome, which may occur even without the 
concomitant use of a serotonergic agent [10,39,61]. In fact, acting as a 5-HT2A antagonist, long-term 
clozapine use may be associated with receptor downregulation, and thus, its abrupt discontinuation 
might lead to receptors’ upregulation [65,66]; d) a sudden decrease in gamma-aminobutyric acid 
(GABA) activity, with the development of catatonic symptoms which may include, mutism, waxy 
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flexibility, staring, posturing, mannerisms, negativism, and also restless, irrelevant speech, and 
psychomotor agitation [6,67]. The clozapine agonist action on GABA receptors can explain both the 
drug-drug interaction between clozapine and benzodiazepines, and the flumazenil therapeutic effect 
in clozapine intoxication cases [6]; and e) a modification of norepinephrine levels, with clozapine 
abrupt discontinuation in chronic patients possibly resulting in an increase in suicidal behavior [1,68]. 
As it may occur with remaining psychotropics, such as antidepressants [69,70], the existence of a 
discontinuation syndrome following an abrupt stoppage of, or marked reduction in, the dosage of a 
drug taken on a regular basis does not necessarily mean that a drug causes dependence. 
Discontinuation should be seen here as distinct from the withdrawal scenario associated with alcohol 
and other addictive substances, a scenario which commonly presents together with craving, drug 
seeking behavior, and the inability to stop drug use [71,72]. Thus, if a discontinuation of clozapine is 
needed, the molecule should be gradually tapered off over several weeks rather than abruptly 
discontinued, except in cases of emergency (e.g., agranulocytosis), and only with close clinical 
monitoring [10,67,73]. There are no established guidelines regarding which antipsychotic to choose 
after withdrawal of clozapine [73], although anticholinergics and olanzapine may be the treatment of 
choice for preventing withdrawal [53]. 
The reporters’ narrative here formally submitted in a few cases was consistent with both drug 
seeking and diversion behavior (e.g., “…clozapine as a drug of abuse…”; and “…patient possibly has 
used Leponex as drug of abuse or he bought Leponex for drug abuse by others…”.). Considering the 
current misuse/abuse issues, the number of clozapine related ADRs (e.g., 326 ADRs; referring to: 
‘drug abuse’, ‘drug abuser’, ‘drug diversion’, ‘intentional product misuse’, ‘product use issue’, and 
‘substance abuse’) here identified may be difficult to interpret. In fact, in comparing quetiapine- and 
other second-generation antipsychotic-related intentional abuse exposures reported to the US 
National Poison Data System, Klein et al. [74] suggested that clozapine and olanzapine were 
significantly associated with frequent instances of severe central effects, including: 
lethargy/drowsiness/slurred speech; agitation/irritability; confusion and hallucinations. However, no 
use of clozapine as a recreational drug was reported. One could argue that at least a proportion of 
these ADRs involved subjects suffering from both schizophrenia and a co-occurring SUD. 
Furthermore, current findings here did not identify any idiosyncratic intake modalities (e.g., 
intravenous use) that are typical of a substance misuse behavior. Hypothetically, putative levels of 
clozapine misuse liability might be tentatively explained considering the range of its 
pharmacodynamics activities, and the occurrence of rewarding and pleasurable effects due to the 
agonism at both delta-opioid [13,17,75] and cannabinoid CB1 receptors [18]; and the antagonism at 
muscarinic receptors [76,77]. Additionally, although clozapine was here ingested on its own in some 
69% of cases, remaining antipsychotics and benzodiazepines were the drugs most frequently 
reported in association. Polypharmacy ingestion may have facilitated the occurrence of synergistic 
reactions, and hence the EMA ADRs’ reporting, due to possible increase in clozapine plasma 
concentrations associated with metabolism inhibition [14]. Relatively small recreational drugs’ 
numbers were identified here as well, and this may have been associated with complex 
pharmacological interactions. Indeed, clozapine pre-treatment may increase cocaine concentrations, 
but significantly reduce subjective responses to cocaine [78]. 
Regarding the ADRs’ outcomes, present figures seem to be a reason for concern, since most cases 
(298/559 = 53.3%) required a prolonged hospitalization. Furthermore, some 46 (8.2% of 559 subjects) 
fatalities were here reported, and these mostly occurred in the context of: high dosage clozapine 
intake; suicidal behavior; and/or polydrug abuse. Although the EMA suggests a maximum clozapine 
dosage of up to 900 mg/day and warns about side-effects occurring at doses over 450 mg/day [79], 
cases reported here were at times associated with massive dosages (e.g., in the range of 2800–5600 
mg), although most of these cases were associated with overdose/suicide instances. These rates are a 
reason for concern but seem to be consistent with the suggestion that those subjects diagnosed with 
treatment-resistant schizophrenia, and hence, who are typically being prescribed with clozapine, 
present with a higher risk of attempted/completed suicide in comparison to the general population 
[80]. Clozapine overdose may be lethal due to changes in heart rhythm, respiratory depression, and 
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altered state of consciousness [4,81,82]; clozapine high-dosage ingestion may be associated with a 
mortality rate of approximately 12% [83], with fatalities most typically being associated with cardiac 
insufficiency and aspiration pneumonia observed with dosages higher than 2 g [45–48]. Although 
cases of full recovery after ingestion of either high dosages [46] and/or associated with very high 
plasma levels (>9000 ng/mL) [45] have been reported, ingestion of 400 mg in a patient not previously 
treated may be life-threatening [46]. 
4.1. Limitations 
Overall, pharmacovigilance systems such as the EV in Europe, the Medicines and Healthcare 
products Regulatory Agency (MHRA) in the United Kingdom and the FDA Adverse Event Reporting 
System (FAERS) are considered important because the analysis of suspected ADRs may deal with 
early detection of possible drug safety signals [34]. However, the study of ADRs alone may not be 
enough to prove causality between a certain suspected reaction and a specific medicine. Any case 
report should be considered and assessed together with all available data, including case reports 
worldwide, clinical trials, epidemiological studies, and toxicological investigations. 
Unfortunately, the dataset did not typically report here any clinical data, including information 
on the current/past psychopathology and the medications that were prescribed in association. 
Furthermore, the study of ADRs may be influenced by the molecule’s availability and extent of use, 
although precise data on the worldwide prescription rates for clozapine were not here identified or 
available. Moreover, in being voluntarily reported/submitted, the number of ADRs could have been 
conditioned by both the nature of the reaction and the public awareness of a safety concern, with 
underreporting possibly having here occurred. Additionally, some data could have been unavailable, 
invalid or redacted. 
4.2. Conclusions 
Current findings focused on a range of clozapine withdrawal and misuse/abuse/dependence 
issues. It was here confirmed, on a large-scale basis, that, following the abrupt reduction of clozapine 
dosage a discontinuation/withdrawal syndrome may occur. This may involve possible severe and 
long-lasting symptoms [10,59,67,84]. Moreover, although this may be an unusual event, it is here 
suggested that cases of misuse/abuse/dependence could occur in patients with a concomitant SUD 
and this is despite clozapine being of clinical value for the treatment of dual diagnosis. Conversely, 
current findings emphasized a range of severe and fatal health consequences associated with 
clozapine high-dosage intake, and patients taking clozapine should be educated thoroughly about 
the risks associated with polydrug intake. In being a prescribed drug of highly significant clinical 
value [85], increased awareness is essential towards prevention, diagnosis, and treatment of cases of 
clozapine abuse/recreational use in patients diagnosed with schizophrenia [86]. 
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